IBI322
innovent biologics
['hodgkin', 'lymphoma', 'innovent']
dcbn news: innovent announces phase 1 clinical data of ibi322 (cd47/pd-l1 bispecific antibody) in the treatment of anti-pd-(l)1-resistant classic hodgkin lymphoma patients at the eha 2023 annual meeting: ... #biotech #news 
Life science news and jobs from Washington DC, Maryland and Virginia. Part of @BiotechNetworks, connecting #biotech since 2008.